Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program
- Authors
- Lee, Jae-Lyun; Park, Se Hoon; Koh, Su-Jin; Lee, Se Hoon; Kim, Yu Jung; Choi, Yoon Ji; Lee, Jihye; Lim, Ho Yeong
- Issue Date
- Nov-2014
- Publisher
- Springer Verlag
- Keywords
- Castration-resistant prostate cancer; Chemotherapy; Cabazitaxel; Prednisolone; Febrile neutropenia
- Citation
- Cancer Chemotherapy and Pharmacology, v.74, no.5, pp 1005 - 1013
- Pages
- 9
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Cancer Chemotherapy and Pharmacology
- Volume
- 74
- Number
- 5
- Start Page
- 1005
- End Page
- 1013
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8815
- DOI
- 10.1007/s00280-014-2579-5
- ISSN
- 0344-5704
1432-0843
- Abstract
- Purpose
To report the efficacy and safety of using cabazitaxel plus prednisolone chemotherapy to treat Korean patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel therapy.
Methods
This cohort study enrolled 26 mCRPC patients. Treatment consisted of 25 mg/m2 cabazitaxel that was intravenously administered every 3 weeks, in addition to twice-daily 5 mg prednisolone.
Results
The median patient age was 67 years (range = 53–82), median Eastern Cooperative Oncology Group performance status was 1 (range = 0–2), Gleason score was ≥8 in 25 patients (96 %), and median serum prostate-specific antigen (PSA) was 95.3 ng/mL (interquartile range = 9.1–297.7). A total of 180 treatment cycles were administered, and a median of five cycles were administered per patient (range = 1–23). A PSA response was observed in 32 % of evaluable patients. Tumor response was evaluated in eight patients, and three and four patients achieved partial response and stable disease, respectively. Over a median follow-up duration of 23.4 months (95 % CI 11.1–35.6), median time to treatment failure was 4.2 months (95 % CI 1.8–6.6) and median time to progression was 8.5 months (95 % CI 3.0–13.1). Median overall survival was 16.5 months (95 % CI 12.1–20.9). Grade 3 or worse febrile neutropenia developed in eight patients (31 %) and neutropenic infection in four patients (15 %).
Conclusion
Cabazitaxel plus prednisolone chemotherapy can be used to treat Korean mCRPC patients. Prophylactic growth factor support should be considered for patients at high risk of neutropenic fever or infection.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.